Please assess the completion status of the following clinical trial:

Trial Title: ICI 182780 in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed adenocarcinoma of the breast~  * Progressive local-regional or metastatic disease~ * Unconfirmed new or progressive multiple pulmonary nodules or unequivocal radiographic evidence of multiple bone metastases allowed~* At least 1 measurable lesion~  * At least 20 mm by CT scan or MRI OR at least 10 mm by spiral CT scan~ * Nonmeasurable disease includes the following:~    * Bone lesions~   * Leptomeningeal disease~   * Ascites~   * Pleural/pericardial effusions~   * Lymphangitis cutis/pulmonis~   * Inflammatory breast disease~   * Abdominal masses not confirmed and followed by imaging techniques~   * Cystic lesions~* Disease progression after prior third-generation aromatase inhibitor (e.g., anastrozole, exemestane, letrozole, or vorozole)~  * Failed no more than 1 prior additive hormonal therapy (e.g., aromatase inhibitor with or without tamoxifen)~    * Disease recurrence identified no more than 12 months since the last prior adjuvant tamoxifen treatment~   * Oophorectomy, ovarian radiotherapy, and luteinizing hormone-releasing hormone (LH-RH) analogs not considered hormonal therapy regimens~* No brain or leptomeningeal metastases~* No hepatic metastases involving more than one-third of the liver~* No symptomatic pulmonary lymphangitic disease~* Evidence of hormone sensitivity as defined by:~  * Relapse after at least 12 months of adjuvant hormonal treatment~ * Tumor remission or stabilization before progression for at least 6 months after prior hormonal therapy for advanced disease~* Postmenopausal as defined by one of the following:~  * At least 12 months since last menstrual period~ * 4-11 months since last menstrual period and follicle-stimulating hormone (FSH) in the postmenopausal range~ * Prior castration and castrate FSH levels within the postmenopausal range~ * Hysterectomy without oophorectomy (FSH in postmenopausal range if age 60 and under)~* Hormone receptor status:~  * Estrogen-receptor and/or progesterone-receptor positive~    * At least 10 fmol/mg cytosol protein OR~   * Positive by immunohistochemistry~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Sex:~* Female~Menopausal status:~* See Disease Characteristics~* Postmenopausal~Performance status:~* ECOG 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~* No history of bleeding diathesis~Hepatic:~* See Disease Characteristics~* Bilirubin no greater than 0.8 mg/dL above upper limit of normal (ULN)~* INR no greater than 1.6~* No hepatitis B or C~* No severe hepatic impairment~Renal:~* Calcium no greater than 10% above ULN~* Creatinine no greater than 1 mg/dL above ULN~* No severe renal impairment~Cardiovascular:~* No unstable or uncompensated cardiac condition~Pulmonary:~* No unstable or uncompensated respiratory condition~Other:~* HIV negative~* No AIDS~* No other severe condition or systemic disease that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Prior trastuzumab (Herceptin) allowed~Chemotherapy:~* Prior adjuvant chemotherapy allowed~* No more than 1 prior chemotherapy regimen for metastatic disease~Endocrine therapy:~* See Disease Characteristics~* More than 4 weeks since prior estrogen replacement therapy~* More than 3 months since prior LH-RH analogs~* No other prior additive hormonal therapy except third-generation aromatase inhibitors or tamoxifen~Radiotherapy:~* See Disease Characteristics~* Concurrent radiotherapy for control of bone pain or other reasons due to established bone lesions allowed if radiotherapy field is no more than 30% of bone marrow~Surgery:~* See Disease Characteristics~Other:~* More than 4 weeks since prior investigational drug for breast cancer~* No concurrent long-term warfarin~* Concurrent bisphosphonates allowed if dose stable~* Concurrent long-term antiplatelet therapy allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fulvestrant (Type: EXPERIMENTAL): Patients receive fulvestrant intramuscularly on day 1. Courses repeat approximately every 28 days in the absence of disease progression or unacceptable toxicity.~Patients are followed every 3 months for 5 years or until disease progression. After disease progression, patients are followed every 3 months for 2 years and then every 6 months for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).